FY2026 EPS Estimates for Belite Bio Reduced by HC Wainwright

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Belite Bio to $1.62 (from $1.89) but reaffirmed a Buy rating with a $200 price target.
• Belite recently beat quarterly EPS expectations (‑$0.38 vs. ‑$0.56 est.), and analysts maintain a consensus target of about $202 as most ratings remain Buy while the stock trades near $173 (market cap ~$6.92B).
• Significant insider selling (CEO sold 9,200 shares; insiders sold 16,500 shares over 90 days) combined with very low institutional ownership (~0.53%) could pressure sentiment and increase volatility.

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Belite Bio in a research report issued on Monday, April 13th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $1.62 per share for the year, down from their previous forecast of $1.89. HC Wainwright has a "Buy" rating and a $200.00 price objective on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q4 2026 earnings at $3.79 EPS.

Belite Bio (NASDAQ:BLTE - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.18.

BLTE has been the topic of several other reports. Morgan Stanley increased their price target on shares of Belite Bio from $191.00 to $201.00 and gave the company an "overweight" rating in a report on Tuesday, March 3rd. Mizuho set a $223.00 target price on shares of Belite Bio in a report on Thursday, February 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Belite Bio in a report on Tuesday, April 7th. Needham & Company LLC set a $217.00 target price on shares of Belite Bio in a report on Tuesday, March 3rd. Finally, Bank of America initiated coverage on shares of Belite Bio in a report on Monday, January 26th. They set a "buy" rating and a $195.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Belite Bio presently has a consensus rating of "Moderate Buy" and a consensus target price of $202.33.

Belite Bio Stock Up 0.2%

Belite Bio stock opened at $173.18 on Tuesday. The stock has a market cap of $6.92 billion, a P/E ratio of -75.30 and a beta of -1.22. Belite Bio has a twelve month low of $53.60 and a twelve month high of $200.00. The company's 50-day moving average price is $172.03 and its two-hundred day moving average price is $143.54.

Institutional Trading of Belite Bio

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd boosted its position in shares of Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company's stock worth $45,000 after acquiring an additional 282 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock worth $87,000 after acquiring an additional 257 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Belite Bio during the 4th quarter worth approximately $103,000. Persistent Asset Partners Ltd acquired a new stake in shares of Belite Bio during the 4th quarter worth approximately $108,000. Finally, GAMMA Investing LLC boosted its position in shares of Belite Bio by 11.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,758 shares of the company's stock worth $130,000 after acquiring an additional 176 shares in the last quarter. Institutional investors and hedge funds own 0.53% of the company's stock.

Insider Transactions at Belite Bio

In other news, CEO Yu-Hsin Lin sold 9,200 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $181.45, for a total transaction of $1,669,340.00. Following the transaction, the chief executive officer directly owned 170,934 shares of the company's stock, valued at approximately $31,015,974.30. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wan-Shan Chen sold 1,100 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $180.43, for a total transaction of $198,473.00. Following the transaction, the director directly owned 9,096 shares in the company, valued at $1,641,191.28. This represents a 10.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 16,500 shares of company stock valued at $2,993,113. 13.29% of the stock is currently owned by company insiders.

Key Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Multiple brokerages have reiterated or raised targets and maintained buy ratings (HC Wainwright reaffirmed a buy with a $200 target; Cantor Fitzgerald, Needham and others have high targets; consensus target ~ $202). This analyst support helps underpin the rally. HC Wainwright Reaffirms Buy
• Positive Sentiment: Recent quarterly results beat expectations (Q1 EPS -$0.38 vs. -$0.56 est.), which investors view as evidence of operational progress for this clinical-stage biotech. MarketBeat BLTE Coverage
• Neutral Sentiment: Articles questioning the timeline to profitability keep longer-term valuation questions in focus; investors may buy the clinical story but watch cash burn and path-to-profit timelines. When Can We Expect A Profit From Belite Bio?
• Neutral Sentiment: Institutional ownership remains unusually low (~0.53% per MarketBeat), which can mean both upside if institutions rotate in, or volatility if they stay absent. MarketBeat Institutional Trading
• Negative Sentiment: Insider selling from top executives: CEO Yu‑Hsin Lin sold 9,200 shares at ~$181.45 (≈5.1% reduction); CFO Hao‑Yuan Chuang sold 6,200 shares at ~$181.50 (≈6.2% reduction). Large executive sales can raise governance/near‑term sentiment concerns. CEO Sale SEC Filing
• Negative Sentiment: Director Wan‑Shan Chen sold 1,100 shares at ~$180.43 (10.8% reduction of her holding), adding to the round of insider exits and putting downward pressure on sentiment. InsiderTrades: Wan-Shan Chen Sale

About Belite Bio

Belite Bio, Inc NASDAQ: BLTE is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.